1. Home
  2. |Professionals
  3. |Shannon Lentz

Shannon Lentz

Partner | She/Her/Hers
Partner | She/Her/Hers
c2xlbnR6QGNyb3dlbGwuY29t
VCard
VCard

Areas of Focus

Overview

Companies and innovators looking for creative solutions to complex intellectual property issues trust Shannon Lentz to think outside the box. Whether it is looking for ways to challenge or defend existing patents, or procuring new ones, Shannon has helped craft strategies that mitigate risk and maximize return on intellectual property investments.

Shannon helps clients challenge or defend patents in District Courts as well as before the U.S. Patent and Trademark Office through post-grant review proceedings. She also advises clients looking to avoid adversarial proceedings while still achieving their business goals.

While Shannon’s practice primarily focuses on pharmaceutical technologies, she has wide-ranging experience in cell and molecular biology, genetics, organic chemistry, pharmaceutical chemistry, polymer chemistry, metallurgy, medical devices, biologics, coatings, adhesives, nanomaterials, research tools, and drug delivery technologies.

Prior to becoming a lawyer, Shannon worked in the Functional Genomics group of the Biological Defense Research Directorate of the Naval Medical Research Center, where she sequenced bacterial and viral genomes using next-generation sequencing technologies.

Career & Education

|

    • University of Maryland School of Law, J.D.
    • University of Maryland, College Park, B.S., molecular biology and genetics
    • University of Maryland School of Law, J.D.
    • University of Maryland, College Park, B.S., molecular biology and genetics

    • District of Columbia
    • Maryland
    • U.S. Patent and Trademark Office (USPTO)
    • District of Columbia
    • Maryland
    • U.S. Patent and Trademark Office (USPTO)

Shannon's Insights

Client Alert | 2 min read | 01.11.24

Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen

On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al.  The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.   ...

View All Insights

Representative Matters

  • Representing LifeNet Health in a five-patent case against Surgalign (f/k/a RTI Surgical) involving soft tissue grafts and spinal implants, successfully defending LifeNet Health’s patents against IPR petitions filed by Surgalign.
  • Represented inventors in a highly contested patent inventorship bench trial in the Central District of California and subsequent appeal to the Federal Circuit involving a pharmaceutical compound.
  • Moderna v. CureVac: Represented patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
  • Apotex v. Amgen, IPR2016-01542 (PTAB): Represented petitioner Apotex in an inter partes review successfully invalidating a patent relating to Neupogen® and Neulasta®.
  • LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal. 
  • Represented university system in patent license dispute over cancer treatment in which the plaintiff pharmaceutical company sought damages exceeding $200 million. Obtained summary adjudication in favor of client.
  • Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.

Shannon's Insights

Client Alert | 2 min read | 01.11.24

Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen

On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al.  The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.   ...

View All Insights

Insights

Client Alert | 2 min read | 01.11.24

Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen

Press Coverage | 01.04.24

Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm

Press Coverage | 01.11.23

Crowell & Moring Promotes Largest Partner Class in Its History

Firm News | 10 min read | 01.09.23

Crowell & Moring Elects 16 New Partners, Promotes Five to Senior Counsel, and 25 to Counsel
|

View All Insights

Practices

Industries

Shannon's Insights

Client Alert | 2 min read | 01.11.24

Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen

On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al.  The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.   ...

View All Insights